skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

This white paper examines the landscape of new drug development and clinical trial activity in heart failure, which affects 5.8 Americans and 23 million people globally. In the past five years, just one new/novel drug has been registered with a regulatory authority for approval, and three other compounds with previous approvals in other indications such as hypertension and angina were also registered for heart failure to see where the future of treatment could lead us.

 

  • The number of heart failure drugs in development by pharma company
  • Phase II and Phase III pipeline drugs, the company developing them and the mechanism of action for each
  • Which companies are leading in the number of Phase III as well as total trials
  • The current state of cell therapies in development, and how their developers could best convince the healthcare community of their viability
  • The countries that are hosting the most clinical trial activity
Innovation In Heart Failure Drug Development

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: